Clinical Trial
Study Details
Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
The purpose of this study is to evaluate the safety of repeat administration of MST-188 during vaso-occlusive crisis of sickle cell disease. Additionally, this study will evaluate the development of acute chest syndrome during VOC and re-hospitalization for recurrence of VOC.
Study Overview
Contacts and Locations
Rady Children's Hospital
San Diego, California
United States
Children's Hospital of Southwest Florida
Fort Myers, Florida 33908
United States
Joe Dimaggio Children's Hospital
Hollywood, Florida 33021
United States
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
United States
University of Iowa Children's Hospital
Iowa City, Iowa
United States
Our Lady of the Lake Children's Hospital
Baton Rouge, Louisiana 70808
United States
Rutgers University
New Brunswick, New Jersey
United States
Medical University of South Carolina
Charleston, South Carolina
United States
T. C. Thompson Children's Hospital
Chattanooga, Tennessee
United States